
New COVID Drugs Face Delays as Trials Get Harder to Do
The success of vaccines has reduced the pool of people available for studies, among other factors
The success of vaccines has reduced the pool of people available for studies, among other factors
“Sexually transmitted” plant viruses may be on the rise because of agricultural activity
New research counters high-profile claims that people who had COVID don’t benefit from vaccination
Such protection declines within months of the mRNA COVID vaccines’ third dose. Yet the vaccines continue to ward off severe disease
Fluvoxamine is both inexpensive and highly effective at preventing mild COVID-19 from turning severe
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account